Oral BPC-157: Does Taking It by Mouth Work? Acid Stability, Rat Studies, the Arginate Claim and the Missing Human Data

Written by Dr. Andrii Kaleniuk. Updated October 27, 2026.

Oral BPC-157 is the version of the peptide that comes in capsules rather than vials, and the honest answer to whether it works is that nobody has measured it in a human being. BPC-157 was discovered in gastric juice and is unusually stable in stomach acid, which is the basis of the claim that it survives digestion, and in rats it has been given by mouth, in drinking water, with effects on the gut and in a few studies on ligaments that matched injection. That is the entire case for the capsule. Against it stands the fact that peptides of this size are generally absorbed at 1 to 2% or less when swallowed, that no human study has ever measured BPC-157 in blood after an oral dose, that the one human trial programme of an oral-type formulation, for ulcerative colitis in 2005, never went beyond a conference abstract, and that the capsules on sale are unregulated products of unknown content.

This article separates what is known from what is assumed: the gastric-stability claim and what it does and does not imply, the animal studies that used oral dosing and what they treated, the arginate-salt bioavailability claims, the human data that exist, what is actually inside a capsule sold online, and where oral BPC-157 stands legally and in sport.

Most peptide drugs are destroyed within minutes in the stomach by acid and pepsin, which is why insulin, GLP-1 drugs and growth-hormone peptides are injected, and why oral semaglutide needed an absorption enhancer and a dose some 50 times higher than the injection. BPC-157 is different in origin. It is a 15-amino-acid sequence taken from a larger protein found in human gastric juice, and the Zagreb group that characterised it in the early 1990s reported that it kept its activity after prolonged exposure to gastric juice in the laboratory. That stability is real and is the one solid fact in the oral argument. It is also a smaller fact than it sounds: surviving acid is necessary for an oral drug but not sufficient. The peptide still has to cross the intestinal wall, avoid the enzymes there, and reach the bloodstream in a meaningful concentration, and for BPC-157 none of those steps has ever been measured in a person. Everything the capsule sellers say about 'high oral bioavailability' is extrapolation from the acid-stability finding, not from absorption data.

The oral evidence rests on rodent work from a single research group, mostly in Zagreb, over three decades. The gut studies are the most consistent: BPC-157 given intragastrically or in drinking water protected rats from stomach ulcers caused by alcohol or NSAIDs, from experimentally induced colitis, from oesophageal and duodenal injury, and improved healing of surgical joins in the bowel and of fistulas. These are tissues the swallowed peptide touches directly, so they say little about absorption. The study most often quoted for systemic effects is Cerovecki and colleagues in 2010, in which rats with a cut medial collateral ligament received BPC-157 either by injection or at 0.16 micrograms per millilitre in their drinking water for 90 days, and both groups healed better than controls by similar margins. A mouse study of urinary incontinence found the same equivalence. That is evidence that something reaches the ligament after oral dosing in a rat; it is not evidence of what dose does so, nor that the same happens in a 90-kilogram human with a different gut. The tendon and muscle studies that fuel most of the interest, including the Achilles and quadriceps work, used injection, as discussed in BPC-157 for tendon recovery and BPC-157 for shoulder pain.

Two forms of BPC-157 are sold: the acetate salt, which is what the research used, and an arginate salt, which some sellers market as the oral-optimised form on the strength of patent filings claiming bioavailability rising from under 3% to over 90%. The published support is a single rat study reporting roughly sevenfold higher oral exposure for the arginate than the acetate, which, if the acetate's true oral bioavailability is around 1 to 2%, would put the arginate in the 10% range, not 90. No human data exist for either salt by mouth, and nothing independent confirms the patent numbers. The arginate is more stable in solution, which is a manufacturing advantage; whether it is a pharmacological one is unknown.

There has never been a randomized trial of BPC-157 in humans for tendon, muscle, joint or gut healing by any route, and there has never been any human study by mouth. The first entry on the list is the closest thing to an oral study, a rectal formulation given to healthy men for safety, and it has no efficacy data.

Capsules sold as BPC-157 fall into two categories, and neither is reviewed by any regulator. Some are sold as 'research chemicals' with a disclaimer against human use, the same framing as injectable vials; the FDA's position, restated in warning letters through 2026, is that products marketed with dosing suggestions or testimonials are being sold as drugs regardless of the label. Others are sold as dietary supplements, which is not lawful either: BPC-157 cannot be a supplement ingredient because it was first investigated as a drug and is not a food substance, and the Department of Defense's supplement safety programme lists it among prohibited ingredients found in wellness products. Independent testing of grey-market peptides has repeatedly found vials and capsules containing less peptide than labelled, a different peptide, or none, alongside bacterial and endotoxin contamination in injectables. A capsule removes the injection risks, infection and endotoxin, and keeps every other one: unknown dose, unknown identity, no quality control, and no evidence that what is absorbed does anything. We do not provide sourcing or dosing information for unapproved products; the legal position by role and country is in is BPC-157 legal in 2026.

If the question is which route the evidence supports, the answer is injection, because that is what almost all the animal studies used, including every tendon and muscle study, and what the limited human safety work covered. If the question is whether capsules are a reasonable workaround for people who will not inject, the answer is that they are a different, less-studied unknown rather than a safer known. The arguments usually made for capsules, that they avoid needles, that BPC-157 is acid-stable, and that rats healed ligaments on oral dosing, are each true and each insufficient on its own. What would settle it is a human oral pharmacokinetic study, which would be simple to run and which no manufacturer has published in thirty years. The side-effect profile, which is largely inferred from animal data and case reports, is set out in BPC-157 side effects.

Swallowing BPC-157 instead of injecting it changes nothing about its regulatory status. It remains an unapproved new drug in the US; it cannot be compounded by pharmacies pending FDA rulemaking after the July 2026 advisory committee vote; it is prohibited at all times under WADA's S0 category for substances not approved for human use; and it appears on the Department of Defense prohibited list. Athletes sometimes assume oral products are safer from a testing standpoint, which is backwards: S0 violations are often established from purchase records and admissions rather than from a urine test, and capsules leave the same paper trail. For non-tested lifters the issue is purely one of evidence and product quality. The compounds most often sold alongside BPC-157, and their own status, are compared in BPC-157 vs TB-500 and the Wolverine stack, and the whole category is surveyed on our bodybuilding peptides page.

Oral BPC-157 rests on one real fact, acid stability, and one set of rat experiments in which drinking-water dosing matched injection for ligament and gut healing. It has no human absorption data, no human efficacy trial by any route, and a product supply with no oversight. That does not prove the capsules do nothing; it means nobody knows, and that the people selling them have had thirty years to find out and have not. Until a human oral pharmacokinetic study exists, 'does oral BPC-157 work' has the same answer as 'does injectable BPC-157 work in humans', which is that the question has never been properly asked.

BPC-157 is an unapproved investigational substance. This article reviews published evidence for general information and does not provide dosing, sourcing or product guidance.